176 related articles for article (PubMed ID: 34791961)
1. An updated patent review of small-molecule c-Met kinase inhibitors (2018-present).
Chu C; Rao Z; Pan Q; Zhu W
Expert Opin Ther Pat; 2022 Mar; 32(3):279-298. PubMed ID: 34791961
[TBL] [Abstract][Full Text] [Related]
2. c-Met kinase inhibitors: an update patent review (2014-2017).
Zhang QW; Ye ZD; Shi L
Expert Opin Ther Pat; 2019 Jan; 29(1):25-41. PubMed ID: 30474428
[TBL] [Abstract][Full Text] [Related]
3. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
4. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
7. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
8. Optimization techniques for novel c-Met kinase inhibitors.
Sun ZG; Yang YA; Zhang ZG; Zhu HL
Expert Opin Drug Discov; 2019 Jan; 14(1):59-69. PubMed ID: 30518273
[TBL] [Abstract][Full Text] [Related]
9. Recent Progress in the Development of Small Molecule c-Met Inhibitors.
Lv PC; Yang YS; Wang ZC
Curr Top Med Chem; 2019; 19(15):1276-1288. PubMed ID: 31526339
[TBL] [Abstract][Full Text] [Related]
10. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present).
Sun X; Xu S; Yang Z; Zheng P; Zhu W
Expert Opin Ther Pat; 2021 Mar; 31(3):223-238. PubMed ID: 33315482
[No Abstract] [Full Text] [Related]
12. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
13. Recent Patents on the Development of c-Met Kinase Inhibitors.
Xu X; Yao L
Recent Pat Anticancer Drug Discov; 2020; 15(3):228-238. PubMed ID: 32603284
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
16. C-MET as a new therapeutic target for the development of novel anticancer drugs.
Cañadas I; Rojo F; Arumí-Uría M; Rovira A; Albanell J; Arriola E
Clin Transl Oncol; 2010 Apr; 12(4):253-60. PubMed ID: 20462834
[TBL] [Abstract][Full Text] [Related]
17. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
18. MET inhibitors in cancer: pitfalls and challenges.
Oliveres H; Pineda E; Maurel J
Expert Opin Investig Drugs; 2020 Jan; 29(1):73-85. PubMed ID: 31783719
[No Abstract] [Full Text] [Related]
19. C-MET inhibitors in the treatment of lung cancer.
Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
[TBL] [Abstract][Full Text] [Related]
20. Developing Antagonists for the Met-HGF/SF Protein-Protein Interaction Using a Fragment-Based Approach.
Winter A; Sigurdardottir AG; DiCara D; Valenti G; Blundell TL; Gherardi E
Mol Cancer Ther; 2016 Jan; 15(1):3-14. PubMed ID: 26712116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
